A randomized clinical trial published in January 2026 has delivered some of the strongest evidence yet that consumer smartwatches, powered by AI-driven heart-rhythm algorithms, can meaningfully catch a dangerous but often silent heart condition before it causes a stroke. The Netherlands-based EQUAL trial found that high-risk older adults who wore an Apple Watch for at least 12 hours a day were more than four times as likely to have atrial fibrillation detected as those who received standard care alone.
Inside the EQUAL Trial
Researchers enrolled 437 participants aged 65 and older who were considered at elevated risk for stroke, randomizing them to six months of smartwatch-based monitoring using an Apple Watch Series 5 or 8, or to standard clinical follow-up without a wearable. Among those who wore the watch for the required 12-plus hours daily, atrial fibrillation was detected in 9.6% of patients, compared with just 2.3% in the control group, according to results presented at the American College of Cardiology’s early-2026 journal scan and published alongside related work in JACC. The study was highlighted as a marquee finding at the Heart Rhythm Society’s 2026 meeting, where Stanford Medicine’s Dr. Marco Perez presented supporting data showing Apple Watch AFib detection running at roughly 86% accuracy in broader populations.
Why Undetected AFib Is Dangerous
Atrial fibrillation is the most common heart-rhythm disorder and a leading contributor to stroke, but it frequently produces no noticeable symptoms, meaning patients can carry it for years without a diagnosis. Paroxysmal AFib — episodes that come and go — is especially hard to catch with a standard in-office EKG, which only captures a brief snapshot of heart activity. Continuous, AI-assisted monitoring built into a wristband addresses that blind spot by watching heart rhythm around the clock and flagging irregular patterns for the wearer to review with a doctor.
A Crowded and Competitive Wearable Market
Apple was first to bring AFib detection to a mainstream smartwatch in 2018, and Google’s Fitbit and Samsung’s Galaxy Watch line followed with comparable features starting in 2020. More recently, smart rings have entered the competition; a study covered by Patient Care Online found a ring-based sensor from Skylabs outperforming the Apple Watch in some detection scenarios, suggesting the underlying AI models and sensor placement both still have room to improve.
Cardiologists Urge Caution Alongside Enthusiasm
Even researchers enthusiastic about the results caution against over-interpreting a positive notification as a diagnosis. A watch-generated AFib alert is a screening signal, not a confirmed medical finding, and cardiologists stress that patients need a follow-up clinical-grade EKG or Holter monitor to confirm the rhythm abnormality before starting treatment such as blood thinners. There is also concern about false positives generating anxiety or unnecessary emergency-room visits among a population of older adults who may not have the digital literacy to interpret notifications correctly, and questions remain about how equitably these benefits reach patients who cannot afford a smartwatch in the first place.
Health-System Implications
Because untreated AFib substantially raises stroke risk, catching more cases earlier could translate into fewer strokes and lower downstream healthcare costs, an argument insurers and health systems are increasingly taking seriously as they consider subsidizing wearables for high-risk patients. Some U.S. health plans have already begun small pilot programs providing smartwatches to patients with risk factors like hypertension or prior stroke.
What Comes Next
Cardiology researchers say the EQUAL trial adds to a growing evidence base — alongside earlier Apple Heart Study data — that will likely push regulators and insurers toward formally recognizing wearable-based AFib screening as a standard-of-care option for high-risk patients rather than a novelty feature. Expect follow-on trials examining whether earlier detection actually reduces stroke rates over multi-year horizons, and continued competition among Apple, Samsung, Google, and ring-makers to refine the underlying algorithms and reduce false alarms. Insurers are also watching the EQUAL results closely, since a wearable that costs a few hundred dollars looks inexpensive next to the tens of thousands of dollars a single stroke hospitalization can cost, and several health plans have begun modeling whether subsidizing smartwatches for high-risk enrollees could ultimately lower total spending, a calculation that could accelerate coverage decisions well ahead of any formal regulatory mandate.
